Melanoma Arising after Imiquimod Use
Open Access
- 9 November 2014
- journal article
- case report
- Published by Hindawi Limited in Case Reports in Medicine
- Vol. 2014, 1-4
Abstract
Imiquimod belongs to the class of 1H-imidazo-[4,5-c]quinolones—drugs originally developed as nucleoside analogues with the aim of finding new potential antiviral agents (Harrison et al., 1988). Indeed, Imiquimod was first released as treatment for genital warts before its actions against skin cancer were studied. Imiquimod is a relatively small sized molecule (Mr = 240.3) and is hydrophobic, allowing it to penetrate the skin epidermal barrier and therefore making it suitable for topical formulations (Gerster et al., 2005). Imiquimod has shown itself effective against skin cancers and precancerous lesions, especially basal cell cancers and actinic keratosis (Salasche et al., 2002, Beutner et al., 1999). There have been reports of Imiquimod being used as topical treatment against cutaneous metastases of melanoma and some authors have reported its use as first-line therapy against melanoma in situ (Smyth et al., 2011, Gagnon, 2011). We report a case of an invasive malignant melanoma arising de novo at the specific site of application of Imiquimod (Aldara cream 5%) for a biopsy-proven superficial BCC. Therefore while Imiquimod has added to our topical armamentarium against skin cancer, care must be exercised in prescribing this treatment and it is especially important to follow up patients regularly.Keywords
This publication has 27 references indexed in Scilit:
- Facial Basal Cell Carcinomas Recurring after Imiquimod TherapyDermatology, 2013
- Treatment of Locally Recurrent Mucosal Melanoma With Topical ImiquimodJournal of Clinical Oncology, 2011
- Topical Imiquimod Treatment of Lentigo MalignaCase Reports in Dermatology, 2009
- Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod creamAustralasian Journal of Dermatology, 2006
- Toll-like receptor function and signalingJournal of Allergy and Clinical Immunology, 2006
- Infiltrative squamous cell carcinoma on the scalp after treatment with 5% imiquimod creamJournal of the American Academy of Dermatology, 2005
- Histologic Resolution of Melanoma In Situ (Lentigo Maligna) With 5% Imiquimod CreamArchives of Dermatology, 2003
- Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trialJournal of the American Academy of Dermatology, 2002
- Imiquimod, a Topical Immune Response Modifier, in the Treatment of Cutaneous Metastases of Malignant MelanomaDermatology, 2002
- The Immune Response Modifiers Imiquimod and R-848 Are Potent Activators of B LymphocytesCellular Immunology, 2000